Hypertensive disease | Sitting systolic blood pressure mean
Item
1. hypertension defined as a mean in-clinic seated cuff systolic blood pressure >150 mmhg at visit 3 (randomisation visit)
boolean
C0020538 (UMLS CUI [1])
C1319893 (UMLS CUI [2,1])
C0444504 (UMLS CUI [2,2])
Diabetes Mellitus, Non-Insulin-Dependent
Item
2. diagnosis of type 2 diabetes mellitus
boolean
C0011860 (UMLS CUI [1])
Age
Item
3. =18 years of age at the date of signing the informed consent
boolean
C0001779 (UMLS CUI [1])
Antihypertensive therapy Discontinue Ability | Absence Risk Unacceptable
Item
4. ability to stop current antihypertensive therapy without unacceptable risk to the patient (investigator's discretion)
boolean
C0585941 (UMLS CUI [1,1])
C1444662 (UMLS CUI [1,2])
C0085732 (UMLS CUI [1,3])
C0332197 (UMLS CUI [2,1])
C0035647 (UMLS CUI [2,2])
C1883420 (UMLS CUI [2,3])
Informed Consent
Item
5. ability to provide written informed consent
boolean
C0021430 (UMLS CUI [1])
Premenopausal state
Item
1. pre-menopausal women (last menstruation <=1 year prior to start of run-in period) who:
boolean
C0232969 (UMLS CUI [1])
Female Sterilization Absent
Item
1. are not surgically sterile; and/or
boolean
C0015787 (UMLS CUI [1,1])
C0332197 (UMLS CUI [1,2])
Breast Feeding | Pregnancy
Item
2. are nursing or pregnant, or
boolean
C0006147 (UMLS CUI [1])
C0032961 (UMLS CUI [2])
Childbearing Potential Contraceptive methods Absent
Item
3. are of child-bearing potential and are not practicing acceptable means of birth control or do not plan to continue practising an acceptable method throughout the study.
boolean
C3831118 (UMLS CUI [1,1])
C0700589 (UMLS CUI [1,2])
C0332197 (UMLS CUI [1,3])
Contraceptive methods Acceptable
Item
the only acceptable methods of birth control are:
boolean
C0700589 (UMLS CUI [1,1])
C1879533 (UMLS CUI [1,2])
Intrauterine Devices
Item
intrauterine device (iud);
boolean
C0021900 (UMLS CUI [1])
Contraceptives, Oral
Item
oral contraceptives (started at least three months prior to start of run-in period)
boolean
C0009905 (UMLS CUI [1])
Contraceptive implant | Injectable contraception
Item
implantable or injectable contraceptives and
boolean
C1657106 (UMLS CUI [1])
C1262153 (UMLS CUI [2])
Patch estrogen
Item
estrogen patch
boolean
C3843379 (UMLS CUI [1])
Night shift worker
Item
2. night shift workers who routinely sleep during the daytime and whose work hours include midnight to 4:00 a.m.
boolean
C0555008 (UMLS CUI [1])
Secondary hypertension | Secondary hypertension Suspected | Renal Artery Stenosis | Pheochromocytoma
Item
3. known or suspected secondary hypertension (e.g., renal artery stenosis, phaeochromocytoma)
boolean
C0155616 (UMLS CUI [1])
C0155616 (UMLS CUI [2,1])
C0750491 (UMLS CUI [2,2])
C0035067 (UMLS CUI [3])
C0031511 (UMLS CUI [4])
Sitting systolic blood pressure mean | Sitting diastolic blood pressure mean
Item
4. mean seated systolic blood pressure (sbp) =180 mm hg and/or mean seated diastolic blood pressure (dbp) =110 mm hg during any visit of the screening and placebo run-in periods
boolean
C1319893 (UMLS CUI [1,1])
C0444504 (UMLS CUI [1,2])
C1319894 (UMLS CUI [2,1])
C0444504 (UMLS CUI [2,2])
Diabetes Mellitus, Insulin-Dependent
Item
5. patients with type 1 diabetes mellitus
boolean
C0011854 (UMLS CUI [1])
Renal dysfunction | Creatinine measurement, serum | Creatinine clearance measurement | Renal Insufficiency Severe
Item
6. renal dysfunction as defined by the following laboratory parameters: serum creatinine >3.0 mg/dl (or >265 µmol /l) or known creatinine clearance <30 ml/min or clinical markers of severe renal impairment
boolean
C3279454 (UMLS CUI [1])
C0201976 (UMLS CUI [2])
C0373595 (UMLS CUI [3])
C1565489 (UMLS CUI [4,1])
C0205082 (UMLS CUI [4,2])
Bilateral renal artery stenosis | Renal Artery Stenosis Kidney Solitary | Status post Kidney Transplantation | Patients Kidney Single
Item
7. bilateral renal artery stenosis, renal artery stenosis in a solitary kidney, post-renal transplant patients or patients with only one kidney
boolean
C0856760 (UMLS CUI [1])
C0035067 (UMLS CUI [2,1])
C0022646 (UMLS CUI [2,2])
C0205171 (UMLS CUI [2,3])
C0231290 (UMLS CUI [3,1])
C0022671 (UMLS CUI [3,2])
C0030705 (UMLS CUI [4,1])
C0022646 (UMLS CUI [4,2])
C0205171 (UMLS CUI [4,3])
Hypokalemia | Hyperkalemia
Item
8. clinically relevant hypokalaemia or hyperkalaemia
boolean
C0020621 (UMLS CUI [1])
C0020461 (UMLS CUI [2])
Sodium uncorrected | Hypovolemia
Item
9. uncorrected sodium or volume depletion
boolean
C0037473 (UMLS CUI [1,1])
C4072785 (UMLS CUI [1,2])
C0546884 (UMLS CUI [2])
Conn Syndrome
Item
10. primary aldosteronism
boolean
C1384514 (UMLS CUI [1])
Hereditary fructose intolerance
Item
11. hereditary fructose intolerance
boolean
C0016751 (UMLS CUI [1])
Biliary Tract Diseases Obstructive | Cholestasis | Hepatic Insufficiency
Item
12. biliary obstructive disorders (e.g., cholestatis) or hepatic insufficiency
boolean
C0005424 (UMLS CUI [1,1])
C0549186 (UMLS CUI [1,2])
C0008370 (UMLS CUI [2])
C1306571 (UMLS CUI [3])
Congestive heart failure New York Heart Association Classification
Item
13. congestive heart failure new york heart academy (nyha) functional class chf iii-iv (refer to appendix 10.3)
boolean
C0018802 (UMLS CUI [1,1])
C1275491 (UMLS CUI [1,2])
Medical contraindication Placebo Run-in Period | Cerebrovascular accident | Myocardial Infarction | Cardiac Surgery procedures | Percutaneous Transluminal Coronary Angioplasty | Angina, Unstable | Coronary Artery Bypass Surgery
Item
14. contraindication to a placebo run-in period (e.g., stroke with-in the past six months, myocardial infarction, cardiac surgery, percutaneous transluminal coronary angioplasty, unstable angina or coronary artery bypass graft within the past three months prior to start of run-in period)
boolean
C1301624 (UMLS CUI [1,1])
C0032042 (UMLS CUI [1,2])
C3274438 (UMLS CUI [1,3])
C0038454 (UMLS CUI [2])
C0027051 (UMLS CUI [3])
C0018821 (UMLS CUI [4])
C2936173 (UMLS CUI [5])
C0002965 (UMLS CUI [6])
C0010055 (UMLS CUI [7])
Tachycardia, Ventricular | Atrial Fibrillation | Atrial Flutter | Cardiac Arrhythmia
Item
15. clinically significant ventricular tachycardia, atrial fibrillation, atrial flutter or other clinically relevant cardiac arrhythmias as determined by the investigator
boolean
C0042514 (UMLS CUI [1])
C0004238 (UMLS CUI [2])
C0004239 (UMLS CUI [3])
C0003811 (UMLS CUI [4])
Hypertrophic Cardiomyopathy | Coronary Artery Disease Obstructive Severe | Aortic Valve Stenosis | Mitral Valve Stenosis
Item
16. hypertrophic obstructive cardiomyopathy, severe obstructive coronary artery disease, aortic stenosis, hemodynamically relevant stenosis of the aortic or mitral valve
boolean
C0007194 (UMLS CUI [1])
C1956346 (UMLS CUI [2,1])
C0549186 (UMLS CUI [2,2])
C0205082 (UMLS CUI [2,3])
C0003507 (UMLS CUI [3])
C0026269 (UMLS CUI [4])
Diabetes Mellitus Unstable Uncontrolled | Hemoglobin A1c measurement
Item
17. patients whose diabetes has not been stable and controlled for at least the past three months as defined by an hba1c >10%
boolean
C0011849 (UMLS CUI [1,1])
C0443343 (UMLS CUI [1,2])
C0205318 (UMLS CUI [1,3])
C0474680 (UMLS CUI [2])
Symptoms Angioedema | Angiotensin-Converting Enzyme Inhibitors | Angiotensin II receptor antagonist
Item
18. patients who have previously experienced symptoms characteristic of angioedema during treatment with angiotensin converting enzyme (ace) inhibitors or angiotensin-ii receptor antagonists
boolean
C1457887 (UMLS CUI [1,1])
C0002994 (UMLS CUI [1,2])
C0003015 (UMLS CUI [2])
C0521942 (UMLS CUI [3])
Substance Dependence
Item
19. history of drug or alcohol dependency within six months prior to signing the informed consent form
boolean
C0038580 (UMLS CUI [1])
Pharmaceutical Preparations Affecting Blood Pressure | Exception Pharmaceutical Preparations Study Protocol
Item
20. concomitant administration of any medications known to affect blood pressure, except medications allowed by the protocol
boolean
C0013227 (UMLS CUI [1,1])
C0392760 (UMLS CUI [1,2])
C0005823 (UMLS CUI [1,3])
C1705847 (UMLS CUI [2,1])
C0013227 (UMLS CUI [2,2])
C2348563 (UMLS CUI [2,3])
Investigational New Drugs
Item
21. any investigational drug therapy within one month of signing the informed consent
boolean
C0013230 (UMLS CUI [1])
Hypersensitivity Investigational New Drugs Component | Telmisartan | Amlodipine | Placebo
Item
22. known hypersensitivity to any component of the study drugs (telmisartan, amlodipine, or placebo)
boolean
C0020517 (UMLS CUI [1,1])
C0013230 (UMLS CUI [1,2])
C1705248 (UMLS CUI [1,3])
C0248719 (UMLS CUI [2])
C0051696 (UMLS CUI [3])
C0032042 (UMLS CUI [4])
Compliance behavior Absent | Protocol Compliance Unable
Item
23. history of non-compliance or inability to comply with prescribed medications or protocol procedures
boolean
C1321605 (UMLS CUI [1,1])
C0332197 (UMLS CUI [1,2])
C0525058 (UMLS CUI [2,1])
C1299582 (UMLS CUI [2,2])
Other medical condition Preventing Completion of clinical trial | Other medical condition Preventing Administration Telmisartan | Other medical condition Preventing Administration Amlodipine
Item
24. any other clinical condition which, in the opinion of the investigator, would not allow safe completion of the protocol and safe administration of telmisartan and amlodipine
boolean
C3843040 (UMLS CUI [1,1])
C1292733 (UMLS CUI [1,2])
C2732579 (UMLS CUI [1,3])
C3843040 (UMLS CUI [2,1])
C1292733 (UMLS CUI [2,2])
C1533734 (UMLS CUI [2,3])
C0248719 (UMLS CUI [2,4])
C3843040 (UMLS CUI [3,1])
C1292733 (UMLS CUI [3,2])
C1533734 (UMLS CUI [3,3])
C0051696 (UMLS CUI [3,4])